2019 Patient & Family Conference (Rockville, Maryland)
Thank you for attending the 2019 Patient & Family Conference in Rockville, Maryland.
Event Date:
Sat, 05/18/2019 - 7:30am
Conference Materials:
Conference Event Type:
Thank you for attending the 2019 Patient & Family Conference in Rockville, Maryland.
If you are interested in learning more about your possible participation in this clinical trial, please complete the form. Your information will be forwarded directly to the sponsoring company.
This PDQ cancer information summary has current information about the treatment of
Immunosuppressive therapy is one therapy option for treatment of patients with lower-risk
Myeloid neoplasms, including
A patient with a diagnosis of myelodysplastic syndrome (MDS) with isolated 5q deletion underwent repeat
Clonal Hematopoiesis is defined as the presence of mutations in peripheral blood in the absence of myeloid malignancies and is thought to occur as a normal part of ageing due to the fitness advantage conferred by these mutations in an ageing hematopoietic compartment.
Hypomethylating agent (HMA) failure myelodysplastic syndrome (MDS) patients have poor outcomes and urgent need for novel therapies. Hedgehog pathway signaling upregulation plays a central role in myeloid neoplasm pathogenesis and leukemia stem cell survival. We evaluated the efficacy and safety of the smoothened inhibitor glasdegib in HMA-failure MDS (n = 35, median age 73 years). According to the